Cloudbreak Pharma Inc. (HKG:2592)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.170
-0.040 (-3.31%)
Jun 18, 2026, 4:08 PM HKT
Market Cap988.14M
Revenue (ttm)1.97M -97.5%
Net Income-526.63M
EPS-0.80
Shares Out 844.57M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume145,000
Open1.170
Previous Close1.210
Day's Range1.150 - 1.210
52-Week Range1.120 - 9.740
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJun 23, 2026

About Cloudbreak Pharma

Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 61
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2592
Full Company Profile

Financial Performance

In 2025, Cloudbreak Pharma's revenue was $253,000, a decrease of -97.52% compared to the previous year's $10.21 million. Losses were -$67.66 million, -31.75% less than in 2024.

Financial numbers in USD Financial Statements